section name header

Information

  1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med. 1971;285(21): 1182-1186.
  2. Kerbel, RS. Tumor angiogenesis. N Engl J Med. 2008;358(19):2039-2049.
  3. Understanding angiogenesis. Angiogenesis Foundation Web site. http://www.angio.org/understanding/process.php. Updated June 23, 2009. Accessed October 1, 2009.
  4. Friedl P, Gilmour D. Collective cell migration in morphogenesis, regeneration, and cancer. Nat Rev Mol Cell Biol. 2009;10:445-457.
  5. Gerhardt H, Golding M, Frutttiger M, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol. 2003;161:1163-1177.
  6. Eaves CJ. SDF-1 tells stem cells to mind their P's and Z's. J Clin Invest. 2005;115(1):27-29.
  7. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastases. Nature. 2001;410(6824):50-56.
  8. Jain RK, Booth MF. What brings pericytes to tumor vessels? J Clin Invest. 2003;112:1134-1136.
  9. Loureiro RM, D'Amore PA. Transcriptional regulation of vascular endothelial growth factor in cancer. Cytokine Growth Factor Rev. 2005;16(1):77-89.
  10. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumor activity. Nat Rev Cancer. 2008;8:579-591.
  11. Kawakami T, Tokunaga T, Hatanaka H, et al. Neuropilin 1 and 2 co-expression is significantly correlated with increased vascularity and poor prognosis in non small cell lung carcinoma. Cancer. 2001; 95(10):2196-2200.
  12. Patan S. Vasculogenesis and angiogenesis. Cancer Treat Res. 2004;117:3-32.
  13. Morabito A, DeMaio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist. 2006;11:753-764.
  14. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82:4-6.
  15. Uzzan B, Nicholas P, Cucherat M, Perret GY. Microvessel density as a prognostic factor in women with breast cancer: a systemic review of the literature and meta-analysis. Cancer Res. 2004;64(9):2941-2955.
  16. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst. 2002;94:883-893.
  17. Weinberg RA. Mechanisms of malignant progression. Carcinogenesis. 2008;29(6):1092-1095.
  18. Li J-L, Harris AL. Notch signaling from tumor cells: a new mechanism of angiogenesis. Cancer Cell. 2005;8:1-3.
  19. Zeng Q, Li S, Chepeha DB, et al. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell. 2005;8(1):13-23.
  20. Dufraine J, Funahashi Y, Kitajewski J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene. 2008;27:5132-5137.
  21. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene. 2008;27:5124-5131.
  22. DePalma M, Venneri MA, Galli R, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell. 2005;8;211-226.
  23. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer. 2008;8:604-617.
  24. Sansone P, Storci G, Tavolari S, et al. IL-6 triggers malignant features of mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest. 2007;117:3988-4002.
  25. Eklund L, Olsen BR. Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res. 2006;312:630-641.
  26. Hayes AJ, Huang WQ, Mallah J, Yand D, Lippman ME, LI L-Y. Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc Res. 1999;58:224-237.
  27. Martin V, Liu D, Fueyo J, Gomez-Manzano C. Tie2: a journey from normal angiogenesis to cancer and beyond. Histol Histopathol. 2008;23:773-780.
  28. Rasmsauer M, D'Amore PA. Contextual role for angiopoietins and TFG1 in blood vessel stabilization. J Cell Sci. 2007;120:1810-1817.
  29. Lewis CE, De Palma M, Naldini L. Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin. Cancer Res. 2007;67:8429-8432.
  30. Shim WSN, Ho IAW, Wong PEH. A TIE(d) balance in tumor angiogenesis. Mol Cancer Res. 2007;5:655-665.
  31. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006;116:2610-2621.
  32. McDonald DM. Tumor blood vessel dynamics during and after angiogenesis inhibition. FASEB J. 2008;22:88.1. [Meeting abstract 22/1/88.1]
  33. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171 a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83-95.
  34. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592-603.
  35. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009;6:327-338.
  36. Harari PM, Allen GW, Bonner JA. Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol. 2007;25:4057-4065.
  37. Pennell, NA, Lynch TJ, Jr. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist. 2009;14(4):399-411.
  38. Gridley T. Notch signaling in vascular development. Development. 2007;134:2709-2718.
  39. Benedito R, Roca C, Sorensen I, et al. The Notch ligands Dll4 and Jagged 1 have opposing effects on angiogenesis. Cell. 2009;137(6):1124-1135.
  40. Reinacher-Schick A, Pohl M, Schmiegel W. Drug insight: antiangiogenic therapies for gastrointestinal cancers: focus on monoclonal antibodies. Nat Clin Pract Gastroenterol Hepatol. 2008;5(5):250-267.
  41. Dotto GP. Crosstalk of Notch with p53 and p63 in cancer growth control. Nat Rev Cancer. 2009;9:587-595.
  42. Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res. 2006;66(24):11520-11536.
  43. Herbst RS, Hong D, Chap L, et al. Safety, pharmacokinetics and antitumor activity of AMG 386, a selective angiopoietin inhibitor in adult patients with advanced solid tumors. J Clin Oncol. 2009;27:3557-3565.
  44. Gridelli C, Rossi A, Maione P, et al. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist. 2009;14:612-620.
  45. Kanthou C, Tozer GM. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol. 2009;90(3):284-294.
  46. ASA404. Novartis Oncology Web site. http://novartisoncology.com/research-innovation/pipeline/asa404.jsp. Accessed October 1, 2009.
  47. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer. 2005; 5:423-435.
  48. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004; 4:335-348.
  49. Novartis Oncology. Exploring the essential role of mTOR in cancer cells. Basel, Switzerland: Novartis Oncology; 2005.
  50. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721-731.
  51. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signaling controls tumour cell growth. Nature. 2006;441:424-430.
  52. Kobayashi S, Kishimoto T, Kamata S, et al. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci. 2007;98:726-733.
  53. Kalaany NY, Sabatini DM. Tumours with P13K activation are resistant to dietary restriction. Nature. 2009;458:725-731.
  54. Nagata Y, Lan K-H, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6(2):117-127.
  55. Nicholson KM, Anderson NG. The protein kinase B/AKT signaling pathway in human malignancy. Cell Signal. 2002;14:381-395.
  56. Chan S. Targeting the mammalian target or rapamycin (mTOR): a new approach to treating cancer. Br J Cancer. 2004;91:1420-1424.
  57. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses AKT-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1 dependent pathways. Nat Med. 2004;10:1013-1023.
  58. Dredge K, Horsfall R, Robinson SP, et al. Orally administered lenalidomide (CC-5013) is antiangiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res. 2005;69:56-63.
  59. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96(17):1788-1795.
  60. Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol. 2001;280:C1375-C1386.
  61. Granger JP, Alexander BT. Abnormal pressure-naturiuresis in hypertension: role of nitric oxide. Acta Physiol Scand. 2000;168:161-168.
  62. Saltz LB, Clarke S, az-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-2019.
  63. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol. 2007;25:4557-4561.
  64. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an antibody against vascular endothelial growth factor antibody for metastatic renal cancer. N Engl J Med. 2003;349(5):427-434.
  65. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med. 2007;356:115-124.
  66. Hutson T, Figlin R, Kuhn J, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist. 2008;13(10):1084-1096.
  67. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24(1):25-35.
  68. Musini VM, Tejani AM, Bassett K, Wright JM. Pharmacotherapy for hypertension in the elderly. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD000028. DOI: 10.1002/14651858.CD000028.pub2
  69. Whitworth JA. World Health Organization (WHO) International Society of Hypertension Writing Group: 2003 World Health Organization (WHO) International Society of Hypertension (ISH) statement on the management of hypertension. J Hypertens. 2002;21:1983-1992.
  70. Dincer M, Altundag K. Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension. Ann Pharmacother. 2006;40:2278-2279.
  71. American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care. 2004;20:S65-S67.
  72. Wang Y-H, Jones DR, Hall SD. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Disposition. 2005; 33:664-671.
  73. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the JNC 7 report. JAMA. 2003;289(19):2560-2571.
  74. Garg RK. Posterior leukoencephalopathy syndrome. Postgrad Med J. 2001;77:24-28.
  75. Glusker P, Recht L, Lane B, et al. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006;354:980-982.
  76. Kapiteijn E, Brand A, Kroep J, Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy, and reversible posterior leukencephalopathy syndrome. Ann Oncol. 2007;18:1745-1747.
  77. Vaughn C. Reversible posterior leukoencephalopathy syndrome in cancer. Curr Oncol Rep. 2008;10(1):86-91.
  78. Avastin [package insert]. South San Francisco, CA: Genentech, Inc; July 2009.
  79. Sutent [package insert]. New York: Pfizer Laboratories; February 2007.
  80. Nexavar [package insert]. Wayne NJ: Bayer Healthcare Pharmaceuticals, Inc; 2009.
  81. Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol. 2006;24:1329-1331.
  82. Ostendorf T, Kunter U, Eitner F. VEGF mediates glomerular endothelial repair. J Clin Invest. 1999;104:913-923.
  83. Martel CL, Presant CA, Ebrahimi B, et al. Bevacizumab-related toxicities: association of hypertension and proteinuria. Comm Oncol. 2006;3:90-93.
  84. Zhu X, Wu S, Dahut W, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: a systematic review and meta-analysis. Am J Kidney Dis. 2007;49(2):186-193.
  85. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006;290:H560-H576.
  86. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
  87. Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol. 2007;14:1860-1869.
  88. Keefe DM, Gibon RJ. Mucosal injury from targeted anti-cancer therapy. Support Care Cancer. 2007;15:483-490.
  89. Gardner-Thorpe J, Grikscheit TC, Ito H, et al. Angiogenesis in tissue-engineered small intestine. Tissue Eng. 2003;9(6):1255-1261.
  90. Wood LS. Managing the side effects of sorafinib and sunitinib. Comm Oncol. 2006;558-562.
  91. Benson AB, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22:2918-2926.
  92. Reidy DL, Chung KY, Timoney JP, et al. Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol. 2007;25:2691-2695.
  93. Grothey A. Biological therapy and other novel therapies in early stage disease: Are they appropriate? Clin Cancer Res. 2007;13:6909s-6912s.
  94. Wolmark N, Yothers G, O'Connell MJ, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08. J Clin Oncol. 2009;27:18s. [suppl; abstr LBA4]
  95. Fingar DC, Richardson CJ, Tee AR et al. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/Eukaryotic translation initiation factor 4E. Mol Cell Biol. 2004;24(1):200-216.
  96. Afinitor [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; April 2009.
  97. Beckwith MC, Tyler LS. Cancer Chemotherapy Manual. St. Louis, MO: Walters Kluwer Health; 2008.
  98. Revlimid [package insert]. Summit, NJ: Celgene Corporation; Jan 2009.